Rezolute (NASDAQ:RZLT) Posts Earnings Results, Beats Expectations By $0.11 EPS

Rezolute (NASDAQ:RZLT) posted its earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11, Zacks reports.

Rezolute Stock Performance

Shares of NASDAQ:RZLT opened at $4.86 on Thursday. The firm has a 50 day moving average of $4.89 and a 200-day moving average of $4.90. Rezolute has a 12 month low of $1.05 and a 12 month high of $6.19.

Insider Buying and Selling

In other Rezolute news, CFO Daron Evans purchased 10,000 shares of the stock in a transaction dated Wednesday, December 18th. The stock was bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the chief financial officer now owns 150,900 shares of the company’s stock, valued at approximately $647,361. This represents a 7.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 18.39% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Wednesday, February 5th. Guggenheim reiterated a “buy” rating on shares of Rezolute in a research note on Monday. Finally, Wedbush restated an “outperform” rating and set a $112.00 target price on shares of Rezolute in a research report on Monday, November 4th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $24.13.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.